FDA Inspection 974566 — Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany

Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany — FEI 2211084

The FDA completed an inspection of Halo Pharmaceutical, Inc. d/b/a Cambrex Whippany on May 27, 2016 in Whippany, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
May 27, 2016
Fiscal Year
2016
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Whippany, NJ (United States)